EOLS Evolus, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1570562 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.1%
TTM net income YoY-16.5%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR28.0%
Net income 3-yr CAGR—
Margins
Gross margin67.2%
Operating margin-15.5%
Net margin-22.3%
FCF margin-15.5%
EBITDA margin-14.0%
Returns
ROE-18,729.6%
ROA-26.8%
ROIC (approx.)-61.1%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets108.2%
Debt / equity—
Current ratio2.27x
Interest coverage-2.06x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $77.95M | $84.08M | $73.14M | $90.30M | $68.97M | $69.39M | $68.52M | $78.95M |
| Cost of revenue | $27.27M | $26.90M | $24.24M | $31.01M | $23.13M | $24.07M | $21.87M | $28.60M |
| Gross profit | $50.69M | $57.18M | $48.90M | $59.29M | $45.84M | $45.32M | $46.66M | $52.63M |
| R&D expense | $1.97M | $1.89M | $2.24M | $3.48M | $2.05M | $1.84M | $2.21M | $2.43M |
| SG&A expense | $52.92M | $57.05M | $51.98M | $54.66M | $52.82M | $56.67M | $56.64M | $50.24M |
| Operating income | -$8.43M | -$4.54M | -$6.85M | $4.22M | -$11.50M | -$10.21M | -$15.17M | -$2.31M |
| Interest expense | $4.25M | $4.17M | $3.98M | $3.98M | $4.09M | $7.21M | $4.42M | $4.57M |
| Pretax income | -$12.23M | -$8.21M | -$10.42M | $515,000 | -$15.57M | -$17.09M | -$18.82M | -$6.35M |
| Income tax | $285,000 | -$154,000 | $256,000 | $385,000 | $167,000 | $53,000 | $72,000 | $440,000 |
| Net income | -$12.52M | -$8.05M | -$10.67M | $130,000 | -$15.74M | -$17.14M | -$18.89M | -$6.79M |
| EBITDA | -$6.85M | -$3.01M | -$4.50M | $6.47M | -$10.36M | -$9.28M | -$13.61M | -$940,000 |
| EPS (basic) | -0.19 | -0.12 | -0.16 | — | -0.24 | -0.27 | -0.30 | — |
| EPS (diluted) | -0.19 | -0.12 | -0.16 | — | -0.24 | -0.27 | -0.30 | — |
| Weighted avg. shares (diluted) | 66.09M | 65.93M | 65.19M | — | 64.73M | 64.54M | 63.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.70M | $45.17M | $49.79M | $53.83M | $43.52M | $61.74M | $67.89M | $86.95M |
| Receivables | $60.28M | $62.38M | $52.22M | $54.70M | $50.44M | $47.71M | $47.45M | $47.68M |
| Inventory | $82.80M | $40.90M | $24.80M | $26.96M | $32.87M | $26.46M | $10.03M | $12.16M |
| Current assets | $201.74M | $167.54M | $138.92M | $142.92M | $134.89M | $144.97M | $131.72M | $151.34M |
| PP&E, net | $4.85M | $5.05M | $5.33M | $5.37M | $5.13M | $3.65M | $3.25M | $3.22M |
| Goodwill | $21.21M | $21.21M | $21.21M | $21.21M | $21.21M | $21.21M | $21.21M | $21.21M |
| Intangibles | $46.73M | $45.69M | $46.74M | $48.04M | $48.72M | $49.35M | $49.36M | $48.75M |
| Total assets | $283.82M | $248.02M | $220.65M | $225.87M | $219.00M | $228.80M | $213.36M | $232.57M |
| Current liabilities | $142.38M | $98.73M | $68.02M | $75.31M | $66.71M | $63.75M | $56.23M | $62.96M |
| Long-term debt | $156.90M | $156.74M | $156.41M | $146.10M | $145.78M | $145.47M | $121.81M | $121.51M |
| Total debt | $156.90M | $156.74M | $156.41M | $146.10M | $145.78M | $145.47M | $121.81M | $121.51M |
| Total liabilities | $321.64M | $278.93M | $249.43M | $248.97M | $247.76M | $247.46M | $219.97M | $227.05M |
| Shareholders' equity | -$37.81M | -$30.90M | -$28.78M | -$23.11M | -$28.76M | -$18.65M | -$6.60M | $5.52M |
| Net debt | $115.20M | $111.57M | $106.62M | $92.27M | $102.26M | $83.74M | $53.91M | $34.55M |
| Shares outstanding | 66.14M | 66.01M | 65.84M | 65.01M | 64.77M | 64.64M | 64.45M | 63.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.93M | -$3.59M | -$9.95M | $12.83M | -$14.67M | -$24.79M | -$15.63M | $4.81M |
| Capital expenditure | $320,000 | $50,000 | $415,000 | $1.48M | $955,000 | $688,000 | $319,000 | $438,000 |
| Free cash flow | -$2.25M | -$3.64M | -$10.37M | $11.35M | -$15.62M | -$25.48M | -$15.95M | $4.37M |
| Investing cash flow | -$1.81M | -$500,000 | -$1.69M | -$2.17M | -$2.16M | -$2.27M | -$1.86M | -$1.36M |
| Financing cash flow | $101,000 | -$365,000 | $7.62M | $77,000 | -$1.77M | $20.66M | -$1.63M | -$1.31M |
| Depreciation & amortization | $1.58M | $1.53M | $2.35M | $2.25M | $1.14M | $932,000 | $1.56M | $1.37M |
| Stock-based compensation | $5.60M | $5.62M | $5.12M | $5.15M | $5.13M | $4.49M | $5.93M | $6.17M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.